BridgeBio Oncology Therapeutics, Inc.
BBOT
$7.40
-$0.29-3.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -90.91% | -97.07% | -158.37% | -30.30% | -42.82% |
| Total Depreciation and Amortization | 244.44% | 273.08% | 248.08% | 248.08% | 3.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 302.22% | 1,328.50% | 2,167.35% | -62.35% | -39.72% |
| Change in Net Operating Assets | 51.30% | -247.45% | 214.75% | -63.69% | -70.60% |
| Cash from Operations | -83.26% | -180.90% | -25.23% | -185.63% | -121.08% |
| Capital Expenditure | 85.19% | -630.00% | -1,172.73% | -1,550.00% | -1,057.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,937.62% | -69.34% | 1,240.86% | 106.52% | 545.47% |
| Cash from Investing | -1,957.15% | -69.61% | 1,241.10% | 106.36% | 542.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -13.46% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -88.85% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 70.05% | -- | -- | -- | -- |
| Cash from Financing | 173.02% | -1,226.92% | -- | -90.50% | -106.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6,826.19% | -431.54% | 1,991.03% | -86.72% | -2,763.79% |